CN102711768B - 用于预防和治疗心衰的组合物和方法 - Google Patents

用于预防和治疗心衰的组合物和方法 Download PDF

Info

Publication number
CN102711768B
CN102711768B CN201080026141.0A CN201080026141A CN102711768B CN 102711768 B CN102711768 B CN 102711768B CN 201080026141 A CN201080026141 A CN 201080026141A CN 102711768 B CN102711768 B CN 102711768B
Authority
CN
China
Prior art keywords
acid
composition
use according
heart failure
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080026141.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102711768A (zh
Inventor
李明
李中玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Publication of CN102711768A publication Critical patent/CN102711768A/zh
Application granted granted Critical
Publication of CN102711768B publication Critical patent/CN102711768B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CN201080026141.0A 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法 Expired - Fee Related CN102711768B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18670909P 2009-06-12 2009-06-12
US61/186,709 2009-06-12
US18790509P 2009-06-17 2009-06-17
US61/187,905 2009-06-17
PCT/IB2010/001410 WO2010143058A1 (en) 2009-06-12 2010-06-11 Compositions and methods for the prevention and treatment of heart failure

Publications (2)

Publication Number Publication Date
CN102711768A CN102711768A (zh) 2012-10-03
CN102711768B true CN102711768B (zh) 2014-04-09

Family

ID=43308481

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201080026141.0A Expired - Fee Related CN102711768B (zh) 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法
CN201080026126.6A Expired - Fee Related CN102740870B (zh) 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080030502.9A Expired - Fee Related CN102548571B (zh) 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法
CN201080026126.6A Expired - Fee Related CN102740870B (zh) 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080030502.9A Expired - Fee Related CN102548571B (zh) 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法

Country Status (6)

Country Link
US (7) US9050277B2 (enExample)
EP (6) EP2440221A4 (enExample)
JP (11) JP6076737B2 (enExample)
CN (6) CN102711768B (enExample)
AU (11) AU2010258355B2 (enExample)
WO (6) WO2010143062A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12397008B2 (en) * 2006-04-13 2025-08-26 Lead Billion Limited Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
WO2010143062A1 (en) * 2009-06-12 2010-12-16 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of coronary heart diseases
KR20140010936A (ko) * 2010-12-23 2014-01-27 후야 바이오사이언스 인터내셔널 엘엘씨 정제된 카디오게닌 이성질체 및 관련된 방법
JP6000521B2 (ja) * 2011-08-10 2016-09-28 株式会社ブルボン 血圧上昇抑制剤
EP2812005B8 (en) * 2012-05-16 2018-10-31 Prairie Berry Europe GmbH Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
CN103623753B (zh) * 2013-11-27 2016-03-23 大兴安岭嘉迪欧营养原料有限公司 大兴安岭野生金老梅总三萜提取物的制备方法
CN103623082B (zh) * 2013-11-29 2016-08-17 江西中医药大学 覆盆子提取物及其应用
US20150174057A1 (en) * 2013-12-24 2015-06-25 Generex Pharamaceutics Inc. Compositions and methods for the prevention and treatment of oral diseases
KR20160113277A (ko) * 2014-01-30 2016-09-28 케민 인더스트리즈, 인코포레이티드 인지 기능을 개선시키기 위한 식물 추출물
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN104971091B (zh) * 2015-06-03 2019-08-13 兴明生物医药技术(上海)有限公司 一种用于制备促进心肌再生药物的提取物的制备方法及其应用
WO2017019182A1 (en) 2015-07-24 2017-02-02 Northeastern University Quantitative magnetic resonance imaging of the vasculature
CA2997659C (en) * 2015-09-04 2023-08-01 Reto ASMIS Methods for treatment of monocyte dysfunction and chronic inflammatory micro- and macro-vascular diseases
CN105106222B (zh) * 2015-09-14 2020-05-08 新乡医学院 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用
CN106581006B (zh) * 2015-10-16 2019-11-29 香港理工大学深圳研究院 三萜类化合物在制备治疗帕金森药物中的应用
CN106153761B (zh) * 2016-06-07 2018-08-14 贵州师范大学 同时检测无籽刺梨果实中3种黄酮类成分的方法
JP7361470B2 (ja) 2016-06-20 2023-10-16 バタフライ ネットワーク，インコーポレイテッド ユーザによる超音波装置の操作を援助するための自動画像取得
CN109562217A (zh) 2016-11-02 2019-04-02 天普大学-联邦高等教育体系 用于降低血液粘稠度、抑制血液循环中的乱流及治愈缗线状形成的系统及方法
EP4559523A3 (en) * 2017-04-25 2026-01-07 Buck Institute for Research on Aging Formulations for extending lifespan and healthspan
CN106946971A (zh) * 2017-04-28 2017-07-14 南宁馨艺荣生物科技有限公司 一种从积雪草中提取积雪草酸的工艺
CN107445855B (zh) * 2017-08-07 2018-12-14 绍兴市逸晨医疗科技有限公司 一种盐酸多西环素杂质c的制备方法
WO2019172174A1 (ja) * 2018-03-05 2019-09-12 日本新薬株式会社 Ｒａｇｅシグナル阻害作用をもつ食品素材
WO2019173435A1 (en) * 2018-03-06 2019-09-12 Epibone, Inc. Injectable off-the- shelf cartilage, tendon, and ligament repair compositions and methods of use
JP7365068B2 (ja) * 2018-07-27 2023-10-19 ノースイースタン ユニバーシティ 血管磁気共鳴画像法による認知症の診断
KR102152182B1 (ko) * 2018-09-05 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 우울 증상 또는 스트레스의 개선, 예방 또는 치료용 조성물
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
WO2020124221A1 (en) 2018-12-21 2020-06-25 ARLANXEO Canada Inc. Continuous process for producing halogenated isoolefin copolymer
CN109884222B (zh) * 2019-01-17 2021-07-13 贵州中医药大学 一种小花清风藤的hplc指纹图谱建立方法
KR102152174B1 (ko) * 2020-03-30 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 인지기능 장애의 개선, 예방 또는 치료용 조성물
CN111643556A (zh) * 2020-07-16 2020-09-11 杭州科倍安生物制药有限公司 一种用于预防和治疗痔疮的药物及其应用
WO2022043407A1 (fr) 2020-08-25 2022-03-03 Laouarem Yousra Compositions destinées au traitement des troubles neurologiques
KR102574207B1 (ko) * 2020-12-03 2023-09-04 경북대학교 산학협력단 뱀무 추출물을 유효성분으로 하는 혈전성 질환 치료 또는 예방용 조성물
CN112587599A (zh) * 2021-01-11 2021-04-02 贵州中医药大学 一种预防急性高原反应的中药组合物
CN112755079A (zh) * 2021-01-18 2021-05-07 杭州科倍安生物制药有限公司 一种预防血栓形成或溶解已形成血栓的药物及其制备方法
CN113367166B (zh) * 2021-05-13 2022-07-26 海南大学 一种褐背蒲桃提取物杀菌剂及其制备方法和应用
CN114028459A (zh) * 2021-11-11 2022-02-11 杭州科贝生物制药有限公司 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用
CN114722066B (zh) * 2022-03-23 2023-04-07 电子科技大学 一种预测材料自旋霍尔电导及反常霍尔电导的方法
CN117257781A (zh) * 2022-06-13 2023-12-22 上海市东方医院（同济大学附属东方医院） 美金刚通过靶向心房心肌细胞谷氨酸受体有效干预房颤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558769A (zh) * 2001-11-21 2004-12-29 ���Ĵ���ѧ 包括大根草有机提取物的组合物及其应用
CN1708313A (zh) * 2002-12-10 2005-12-14 香港中文大学 柔毛水杨梅的有机提取物及其应用
CN101406537A (zh) * 2007-10-11 2009-04-15 首都医科大学 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2871763B2 (ja) * 1989-12-15 1999-03-17 株式会社資生堂 テストステロン―５α―レダクターゼ阻害剤
CN1069629A (zh) 1991-08-27 1993-03-10 段民生 一种康复面的制备方法
CN1047089C (zh) * 1992-12-03 1999-12-08 张斌 治疗近视眼的药物及制备工艺
CN1102993A (zh) 1993-12-21 1995-05-31 吴文才 多酶体系加工中草药的制剂方法
JPH07179347A (ja) * 1993-12-21 1995-07-18 Showa Shell Sekiyu Kk 抗ウイルス組成物
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
CA2289531C (en) 1997-05-15 2009-09-29 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
CN1176814A (zh) 1997-06-26 1998-03-25 李静 预防和治疗脑血管病的口服液
CN1102399C (zh) 2000-06-09 2003-03-05 张庆玉 降脂通脉胶囊
AU2001278341A1 (en) * 2000-07-26 2002-02-05 Vitaplant Ag Piper methysticum plant extract
WO2002009720A1 (en) * 2000-07-31 2002-02-07 University Of Virginia Patent Foundation Inhibitors of dna polymerase sigma
US6629835B2 (en) 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
JP2002255804A (ja) * 2001-03-02 2002-09-11 Suntory Ltd インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物
WO2002078685A1 (en) 2001-03-30 2002-10-10 The Nisshin_Oillio, Ltd. Drugs for vascular lesion
KR100453569B1 (ko) * 2001-09-11 2004-10-20 대한민국 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는항산화제
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JP4393777B2 (ja) 2002-03-19 2010-01-06 株式会社ファンケル 抗ヘリコバクター・ピロリ用組成物
CN1239155C (zh) * 2003-01-23 2006-02-01 北京中医药大学 一种治疗缺血性脑中风的药物组合物及其制备方法
US20040247698A1 (en) * 2003-06-04 2004-12-09 Valenzuela Cortes Carmen Maria Erectile Dysfunction Treatment
US20070249711A1 (en) * 2003-10-10 2007-10-25 Wonrack Choi Triterpene Compounds which are Effective on Improvement of Brain Function
CN1185007C (zh) 2003-12-08 2005-01-19 张小朋 降脂溶栓药物
CN100509008C (zh) * 2004-04-12 2009-07-08 赵晓昂 舒痛方及其制剂和用途
WO2006054370A1 (en) * 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
KR100704003B1 (ko) * 2005-06-10 2007-04-06 안동대학교 산학협력단 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물
JP2006347967A (ja) * 2005-06-16 2006-12-28 Yuusu Techno Corporation:Kk 血糖値上昇抑制剤
WO2007049089A1 (en) * 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
WO2007049088A1 (en) 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
AU2006308338B2 (en) 2005-10-27 2009-11-05 Lead Billion Limited Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
KR100718602B1 (ko) * 2005-12-29 2007-06-21 대한민국 항비만 및 항염증 효과를 가지는 뱀무 추출물, 이를포함하는 식품 조성물 및 이들의 제조 방법
JP2007204447A (ja) * 2006-02-03 2007-08-16 Yoshihiro Futamura 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品
JP4731350B2 (ja) 2006-02-17 2011-07-20 丸善製薬株式会社 抗老化剤、皮膚化粧料及び美容用飲食品
CA2646240A1 (en) * 2006-03-16 2007-09-20 Xuemin Shi Combination therapy for treatment of patients with neurological disorders and cerebral infarction
CN1857627B (zh) * 2006-04-12 2010-05-19 贵阳利多药物技术开发有限公司 治疗中风的中药制剂及其制备方法
US8821947B2 (en) 2006-06-01 2014-09-02 Howard W. Selby, III Cholesterol-reducing diet
CN101091751A (zh) * 2006-06-22 2007-12-26 北京中医药大学 一种治疗高血压的中药组合物及其制备方法
JP5281234B2 (ja) * 2006-06-27 2013-09-04 ポーラ化成工業株式会社 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物
CN100528195C (zh) * 2006-06-28 2009-08-19 海南晨菲药业有限公司 一种大青根注射剂制备工艺
CN101099770A (zh) 2006-07-04 2008-01-09 北京中医药大学 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用
JP2008074801A (ja) 2006-09-25 2008-04-03 Oriza Yuka Kk 肝保護剤
JP5366358B2 (ja) * 2006-09-29 2013-12-11 株式会社コーセー 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法
CN101040901A (zh) 2007-04-12 2007-09-26 云南龙润药业有限公司 迷迭香提取物及其制备方法和应用
US9205112B2 (en) 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
US20100189830A1 (en) 2007-05-21 2010-07-29 Zhijun Liu Sweet Gum Fruit Extract as a Therapeutic Agent
US20090022827A1 (en) * 2007-07-19 2009-01-22 Ming Li Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells
CN101125171B (zh) 2007-08-20 2010-05-26 刘凤元 一种男、女补强中药
KR100891881B1 (ko) 2007-08-23 2009-04-07 대한민국 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물
CN101274012B (zh) 2008-01-23 2011-12-28 上海海天医药科技开发有限公司 夏枯草属植物提取物的组合物、制备方法及其药物用途
WO2010143062A1 (en) 2009-06-12 2010-12-16 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of coronary heart diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558769A (zh) * 2001-11-21 2004-12-29 ���Ĵ���ѧ 包括大根草有机提取物的组合物及其应用
CN1708313A (zh) * 2002-12-10 2005-12-14 香港中文大学 柔毛水杨梅的有机提取物及其应用
CN101406537A (zh) * 2007-10-11 2009-04-15 首都医科大学 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李建宽.柔毛水杨梅(Geum Japonicum Thunb. Vax. Chinese F. Bolle)诱导血管形成和心肌再生功能的活性物质研究.《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》.2007,(第01期),第E057-84页. *
柔毛水杨梅(Geum Japonicum Thunb. Vax. Chinese F. Bolle)诱导血管形成和心肌再生功能的活性物质研究;李建宽;《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》;20070115(第01期);第14-18页，第46-47页 *

Also Published As

Publication number Publication date
JP2017128608A (ja) 2017-07-27
AU2010258351B2 (en) 2015-05-21
AU2010258355A1 (en) 2012-02-02
JP2015155468A (ja) 2015-08-27
AU2018202291A1 (en) 2018-04-26
WO2010143061A1 (en) 2010-12-16
AU2010258358B2 (en) 2015-12-10
CN102548560B (zh) 2016-01-20
US9050277B2 (en) 2015-06-09
EP2440221A1 (en) 2012-04-18
EP2440222A1 (en) 2012-04-18
WO2010143065A1 (en) 2010-12-16
EP2440223A1 (en) 2012-04-18
CN102740870B (zh) 2016-06-29
JP2012529485A (ja) 2012-11-22
JP5689117B2 (ja) 2015-03-25
AU2016201525A1 (en) 2016-03-24
JP2012529484A (ja) 2012-11-22
CN102548571A (zh) 2012-07-04
US20120177759A1 (en) 2012-07-12
EP2440212A1 (en) 2012-04-18
AU2010258352A1 (en) 2012-02-02
WO2010143063A1 (en) 2010-12-16
WO2010143059A1 (en) 2010-12-16
CN102740870A (zh) 2012-10-17
AU2010258356A1 (en) 2012-02-02
CN102548571B (zh) 2014-08-27
AU2010258356B2 (en) 2017-01-19
AU2017202572B2 (en) 2019-02-21
AU2017202573A1 (en) 2017-05-11
US9950019B2 (en) 2018-04-24
AU2010258358A1 (en) 2012-02-02
EP2440220A4 (en) 2012-12-12
CN102497873A (zh) 2012-06-13
CN102497873B (zh) 2016-04-13
US20120082741A1 (en) 2012-04-05
CN102711768A (zh) 2012-10-03
US9283255B2 (en) 2016-03-15
AU2016202674A1 (en) 2016-05-19
EP2440209A4 (en) 2013-03-20
JP2012529488A (ja) 2012-11-22
EP2440221A4 (en) 2012-12-12
JP2015164963A (ja) 2015-09-17
WO2010143062A1 (en) 2010-12-16
JP6076737B2 (ja) 2017-02-08
JP5712207B2 (ja) 2015-05-07
US20120148691A1 (en) 2012-06-14
EP2440222A4 (en) 2012-12-12
AU2010258352B2 (en) 2016-04-28
US20120076878A1 (en) 2012-03-29
JP5827618B2 (ja) 2015-12-02
AU2010258351A1 (en) 2012-02-02
AU2017202572A1 (en) 2017-05-11
EP2440220A1 (en) 2012-04-18
EP2440223A4 (en) 2012-12-12
JP6187831B2 (ja) 2017-08-30
JP2012529483A (ja) 2012-11-22
JP2012529487A (ja) 2012-11-22
WO2010143058A1 (en) 2010-12-16
JP5892929B2 (ja) 2016-03-23
CN102573865A (zh) 2012-07-11
US20180055896A1 (en) 2018-03-01
AU2010258354B2 (en) 2015-08-13
US9629884B2 (en) 2017-04-25
CN102548560A (zh) 2012-07-04
US20120077761A1 (en) 2012-03-29
AU2010258354A1 (en) 2012-02-02
AU2017202573B2 (en) 2019-02-21
CN102573865B (zh) 2016-08-24
JP2012529486A (ja) 2012-11-22
JP2015164967A (ja) 2015-09-17
EP2440212A4 (en) 2013-03-20
JP2015164966A (ja) 2015-09-17
AU2010258355B2 (en) 2016-04-28
EP2440209A1 (en) 2012-04-18
JP5892928B2 (ja) 2016-03-23
US20120077762A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CN102711768B (zh) 用于预防和治疗心衰的组合物和方法
US10238676B2 (en) Application of ginsenoside RG3 in preparing medicine for preventing and/or treating dementia, and medicine for treating dementia
US20220152070A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease
Chang et al. Analysis of cardioprotective effects using purified Salvia miltiorrhiza extract on isolated rat hearts
AU2019248307C1 (en) Pharmaceutical composition and application thereof
US20210038668A1 (en) Traditional chinese medicine composition for preventing and/or treating ischemic reperfusion injury
WO2021037244A1 (zh) 一种药物组合物及其应用
Wu et al. Propofol improves intestinal ischemia-reperfusion injury in rats through NF-κB pathway
Chen et al. Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT
Min et al. Renal protective activity of Hsian-tsao extracts in diabetic rats
CN110123883A (zh) 虎杖及虎杖苷、大黄素在治疗类风湿性关节炎中的应用
KR101999538B1 (ko) 담즙산을 포함하는 허혈성 재관류 손상의 예방 또는 치료용 약학적 조성물
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
CN111588763B (zh) 血栓通脉药物、制备方法及含量测定方法
RU2805492C1 (ru) Способ коррекции постпрандиальной гликемии
RU2805492C9 (ru) Способ коррекции постпрандиальной гликемии
US20200101096A1 (en) Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease
CN110664826A (zh) 一种麦冬皂苷d’制剂及其降血糖药物新用途
US20050037100A1 (en) Utilization of extracts from iris plants, cimicifuga racemose and tectorigenin as an estrogen-like organ-selective medicament without uterotropic
US20250114422A1 (en) Composition for lipolysis comprising extract of morus alba l. bark and magnolia officinalis bark as active ingredient
CN110664828A (zh) 一种麦冬皂苷d制剂及其降血糖药物新用途
KR20030030336A (ko) 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를함유하는 약학적 제제
CN110664825A (zh) 一种麦冬皂苷d’制剂及其降血脂药物新用途
Semenova et al. 20-Hydroxyecdysone Partially Alleviates Ischemia/Reperfusion-Induced Damage of Mouse Hind Limb Skeletal Muscle
CN108685896B (zh) 千层纸素a在制备治疗和/或预防慢性周围血管闭塞性疾病药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20170611